HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing Platform.
HIV-specific T cells
conserved epitopes
immunotherapy
latent reservoir
viral escape
Journal
Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857
Informations de publication
Date de publication:
13 Mar 2020
13 Mar 2020
Historique:
received:
04
08
2019
accepted:
03
10
2019
entrez:
14
11
2019
pubmed:
14
11
2019
medline:
14
11
2019
Statut:
epublish
Résumé
Although anti-retroviral therapy (ART) is successful in suppressing HIV-1 replication, HIV latently infected reservoirs are not eliminated, representing a major hurdle in efforts to eradicate the virus. Current strategies to eradicate HIV involve two steps: (1) the reactivation of latently infected cells with latency reversing agents (LRAs) to expose persisting HIV, and (2) the elimination of these cells with immune effectors while continuing ART to prevent reinfection. HIV-specific T cells (HSTs) can kill reactivated HIV-infected cells and are currently being evaluated in early-stage immunotherapy trials. HIV can mutate sequences in T cell epitopes and evade T cell-mediated killing of HIV-infected cells. However, by directing T cells to target multiple conserved, non-escaped HIV epitopes, the opportunity for viral escape can be reduced. Using a good manufacturing practice (GMP)-compliant platform, we manufactured HSTs against non-escape epitope targets (HST-NEETs) from HIV
Identifiants
pubmed: 31720305
doi: 10.1016/j.omtm.2019.10.001
pii: S2329-0501(19)30109-3
pmc: PMC6838524
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11-20Subventions
Organisme : NIAID NIH HHS
ID : P30 AI087714
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL132791
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI131798
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA148600
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI126617
Pays : United States
Informations de copyright
© 2019 The Author(s).
Références
Science. 1997 Nov 14;278(5341):1291-5
pubmed: 9360926
Sci Transl Med. 2018 May 2;10(439):
pubmed: 29720451
Mol Ther. 2015 Feb;23(2):387-95
pubmed: 25366030
J Virol. 1999 Aug;73(8):6721-8
pubmed: 10400770
J Virol. 2017 Mar 29;91(8):
pubmed: 28179531
Blood. 1997 Sep 15;90(6):2196-206
pubmed: 9310470
Biol Blood Marrow Transplant. 2016 Mar;22(3):536-41
pubmed: 26721209
Nature. 2015 Jan 15;517(7534):381-5
pubmed: 25561180
Science. 1997 Nov 21;278(5342):1447-50
pubmed: 9367954
J Clin Invest. 2018 Feb 1;128(2):876-889
pubmed: 29355843
J Virol. 1994 Jul;68(7):4650-5
pubmed: 8207839
J Virol. 2003 Feb;77(3):2081-92
pubmed: 12525643
J Immunol. 1999 Feb 1;162(3):1780-8
pubmed: 9973442
Mol Ther. 2018 Oct 3;26(10):2496-2506
pubmed: 30249388
Virology. 2013 Nov;446(1-2):268-75
pubmed: 24074590
J Infect Dis. 2015 Jul 15;212(2):258-63
pubmed: 25589335
Blood. 2010 Feb 4;115(5):925-35
pubmed: 19880495
Sci Transl Med. 2012 Feb 29;4(123):123ra25
pubmed: 22378925
J Virol. 2001 Jul;75(14):6508-16
pubmed: 11413318
Blood. 2000 Aug 1;96(3):785-93
pubmed: 10910888
PLoS Pathog. 2015 Feb 27;11(2):e1004658
pubmed: 25723536
Immunity. 2012 Mar 23;36(3):491-501
pubmed: 22406268
Blood. 2011 May 19;117(20):5391-402
pubmed: 21422474
Nat Med. 1995 Apr;1(4):330-6
pubmed: 7585062
Science. 1997 Nov 14;278(5341):1295-300
pubmed: 9360927
Mol Ther. 2002 Jun;5(6):788-97
pubmed: 12027564
Mol Ther. 2018 Jun 6;26(6):1435-1446
pubmed: 29724686
J Virol. 2018 Nov 12;92(23):
pubmed: 30209173
J Exp Med. 2009 Jun 8;206(6):1253-72
pubmed: 19487423
Sci Transl Med. 2014 Jun 25;6(242):242ra83
pubmed: 24964991
Mol Ther. 2016 Apr;24(4):832-42
pubmed: 26743582
Nat Med. 1995 Dec;1(12):1284-90
pubmed: 7489410
Mol Ther. 2013 Nov;21(11):2113-21
pubmed: 23783429
Blood. 1999 Mar 1;93(5):1506-10
pubmed: 10029578
Blood. 1993 Apr 15;81(8):2093-101
pubmed: 8471768
PLoS One. 2014 Dec 26;9(12):e115987
pubmed: 25541967